Chembio Diagnostics' (CEMI) CEO Letter to Stockholders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. AXP
10. ZETA

Go back to Chembio Diagnostics' (CEMI) CEO Letter to Stockholders

Chembio’s CEO Letter to Stockholders

April 3, 2023 4:15 PM EDT

MEDFORD, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.

April 3, 2023

Fellow Chembio Stockholders,

As previously communicated, Chembio Diagnostics, Inc. (Chembio or the Company) entered into an Agreement and Plan of Merger (the Merger Agreement), dated as of January 31, 2023, with Biosynex SA (Biosynex), and Project Merci Merger Sub, Inc., a Nevada corporation and wholly-owned indirect subsidiary of Biosynex (the Purchaser). Pursuant to the Merger... More